About 200 reports

TABLE OF CONTENTS ##.

  • Dermatological Condition
  • Managed Care
  • United States
  • Market Size
  • Allergan plc
  • GLOBAL SCLERODERMA TREATMENT MARKET BY OTHERS DRUG CLASS 2016-2021 ($ MILLIONS)
  • COMPETITIVE SCENARIO

Long-term use of analgesics causes gastrointestinal problems.

  • Dermatological Condition
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • MERCK & COMPANY
  • PRODUCT DESCRIPTION

SYSTEMIC TETRACYCLINE MAY CAUSE GASTROINTESTINAL UPSET, NAUSEA, DIARRHEA, AND VAGINAL YEAST INFECTION.

  • Dermatological Condition
  • Managed Care
  • World
  • Market Size
  • Galderma S.A.
  • Epidemiology Analysis
  • PRICING, REIMBURSEMENT, AND REGULATORY STRATEGY B-244 FOR ACNE AND AD

Patients will be randomized (##:##) to MSB-## or placebo for one week.

  • Dermatological Condition
  • Gastrointestinal Drug
  • Therapy
  • United States
  • Synthetic Biologics

Students are also demonstrated the examination of gastrointestinal endoscopy.

  • Healthcare
  • Managed Care
  • Medical Education
  • World
  • Market Size
  • DERMATOLOGY PRODUCTS AND R&D PIPELINE - ALLERGAN
  • 10.7 COMPETITIVE ANALYSIS IN ROSACEA MARKET

Particularly PDE-## and PDL-## inhibitors, the market is huge.

  • Dermatological Condition
  • Managed Care
  • World
  • Forecast
  • Galderma S.A.
  • 2.3.3 Psoriasis
  • Appendix

Minor AEs such as stomatitis, headaches, fatigue and gastrointestinal problems such as nausea and vomiting may occur when using Metolate.

  • Dermatological Condition
  • World
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.

It acquired Salix Pharmaceuticals in 2015 to enter the gastrointestinal segment and divested some of the key brands such as AMBI.

  • Dermatological Condition
  • Forecast
  • Almirall, S.A.
  • Galderma S.A.
  • Valeant Pharmaceuticals International, Inc.
  • Vendor landscape

It also focuses on developing and introducing new treatments in the areas of dermatology, neurology, and gastrointestinal disorders.

  • Dermatological Condition
  • World
  • Bayer AG
  • Mylan Inc.
  • Valeant Pharmaceuticals International, Inc.

It is growing by ##%-##% year on year.

  • Dermatological Condition
  • Managed Care
  • World
  • Forecast
  • Market Segment
  • Dermatology Therapeutics Market, Global, Pipeline Programs Targeting ORAI1, 2017
  • 4.4.3 Psoriasis

It is also in development for various indications in the gastrointestinal, respiratory, and ophthalmology therapy areas.

  • Dermatological Condition
  • World
  • Market Size
  • Allergan plc
  • Apricus Biosciences, Inc.
  • VI. RISK FACTORS
  • a. Approved Products

RISK FACTORS severe acne was related to a higher prevalence of one or more gastrointestinal, sinopulmonary, and psychological co-morbid disorders.

  • Dermatological Condition
  • Allergan plc
  • Foamix Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • a. Approved Products
  • VI. RISK FACTORS

RISK FACTORS severe acne was related to a higher prevalence of one or more gastrointestinal, sinopulmonary, and psychological co-morbid disorders.

  • Dermatological Condition
  • Allergan plc
  • Foamix Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • 2.4 Co-morbidities and Complications
  • Pipeline Landscape Assessment

Minor AEs such as stomatitis, headaches, fatigue and gastrointestinal problems such as nausea and vomiting may occur when using methotrexate.

  • Dermatological Condition
  • World
  • Market Size
  • Amgen Inc.
  • Biologics, Inc.

We are one of the nation' s Top ## health systems.

  • Managed Care
  • United States
  • Company
  • Supply
  • GlobalData's company

DERMATOLOGY ONLINE JOURNAL; ##(##): ## EADY EA, ET AL. (1994).

  • Dermatological Condition
  • Managed Care
  • Foamix Ltd.
  • Galderma S.A.
  • Novan, Inc.
  • DESCRIPTION OF DISORDERS

Systemic tetracycline may cause gastrointestinal upset, nausea, diarrhea, and vaginal yeast infection.

  • Dermatological Condition
  • Managed Care
  • Allergan plc
  • Galderma S.A.
  • Pfizer Inc.
  • FDA
  • Global Acne Grading System

A study reported that severe acne was related to a higher prevalence of one or more gastrointestinal, sinopulmonary, and psychological co-morbid disorders.

  • Dermatological Condition
  • India
  • Allergan plc
  • Cipla Ltd
  • Novartis AG

You can easily book an appointment with one online.

  • Acne Treatment
  • Dermatological Condition
  • Pharmaceutical
  • Allergan plc
  • Galderma S.A.

Asian Nursing Research; ##(##): ##-##.

  • Dermatological Condition
  • Managed Care
  • Actimmune group
  • Anacor Pharmaceuticals, Inc.
  • Astellas Pharma Inc.

The company' s digestive health products include diagnostics and therapeutics, gastrointestinal endoscopy products, enteral feeding tubes and accessories.

  • Respiratory Monitoring
  • Eastern Europe
  • Russia
  • Forecast
  • CareFusion Corporation
  • 7 Pipeline Assessment

Asian Nursing Research; ##(##): ##-##.

  • Dermatological Condition
  • Managed Care
  • Actimmune group
  • Anacor Pharmaceuticals, Inc.
  • Novartis AG
  • 7 Pipeline Assessment

Asian Nursing Research; ##(##): ##-##.

  • Dermatological Condition
  • Managed Care
  • Actimmune group
  • Anacor Pharmaceuticals, Inc.
  • Novartis AG
  • 7 Pipeline Assessment

Asian Nursing Research; ##(##): ##-##.

  • Dermatological Condition
  • Managed Care
  • Actimmune group
  • Anacor Pharmaceuticals, Inc.
  • Novartis AG

GASTROINTESTINAL COMPLICATIONS ARE COMMON AND INCLUDE IMPAIRED MOTILITY, DIGESTION, ABSORPTION, AND EXCRETION DUE TO THE ATROPHY OF THE GASTROINTESTINAL (GI) TRACT.

  • Autoimmune Disease
  • Dermatological Condition
  • Managed Care
  • GlobalData's company
  • Roche Group

PLOS ONE; ##(##): E##.

  • Dermatological Condition
  • Managed Care
  • World
  • Allergan plc
  • Cellceutix Corporation

PLOS ONE; ##(##): E##.

  • Dermatological Condition
  • Managed Care
  • Cempra, Inc.
  • Debiopharm Group
  • Melinta Therapeutics, Inc.

PLOS ONE; ##(##): E##.

  • Dermatological Condition
  • Managed Care
  • Cempra, Inc.
  • Debiopharm Group
  • Melinta Therapeutics, Inc.

PLOS ONE; ##(##): E##.

  • Dermatological Condition
  • Managed Care
  • Cempra, Inc.
  • Debiopharm Group
  • Melinta Therapeutics, Inc.
  • Dormant Products, H1 2018 (Contd..1), H1 2018

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Pipeline Review, H1 2018 Summary Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis...

  • Dermatological Condition
  • Therapy
  • United States
  • World
  • Product Initiative